SANA
Sana Biotechnology, Inc. NASDAQ Listed Feb 4, 2021$3.50
Mkt Cap $934.0M
52w Low $1.60
38.4% of range
52w High $6.55
50d MA $3.36
200d MA $3.94
P/E (TTM)
-3.4x
EV/EBITDA
-5.8x
P/B
5.2x
Debt/Equity
0.5x
ROE
-151.8%
P/FCF
-7.1x
RSI (14)
—
ATR (14)
—
Beta
2.06
50d MA
$3.36
200d MA
$3.94
Avg Volume
3.2M
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
188 East Blaine Street · Seattle, WA 98102 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.13 | -0.16 | -23.1% | 3.93 | -2.3% | -2.8% | -13.2% | -19.8% | -15.3% | -16.3% | — |
| Nov 6, 2025 | AMC | -0.18 | -0.15 | +16.7% | 4.05 | -3.5% | +1.0% | +1.7% | +4.7% | +0.2% | -9.6% | — |
| Aug 11, 2025 | AMC | -0.20 | -0.16 | +20.0% | 2.92 | -0.7% | +6.5% | +14.0% | +17.5% | +14.0% | +16.4% | — |
| May 8, 2025 | AMC | -0.22 | -0.20 | +9.1% | 1.81 | -7.2% | +0.6% | +10.5% | -0.6% | -1.7% | -5.5% | — |
| Mar 17, 2025 | AMC | -0.25 | -0.23 | +8.0% | 2.77 | +2.5% | -17.7% | -15.5% | -18.4% | -16.6% | -12.6% | — |
| Nov 8, 2024 | AMC | -0.26 | -0.25 | +3.8% | 3.01 | +2.7% | -4.0% | -5.6% | -11.6% | -14.0% | -19.6% | — |
| Aug 8, 2024 | AMC | -0.27 | -0.32 | -18.5% | 4.66 | +7.3% | +5.4% | +4.9% | +5.2% | +1.9% | +7.1% | — |
| May 8, 2024 | AMC | -0.30 | -0.32 | -6.7% | 9.49 | -2.4% | -21.0% | -20.3% | -16.6% | -9.4% | -2.3% | — |
| Feb 29, 2024 | AMC | -0.37 | -0.35 | +5.4% | 10.04 | +14.5% | +12.3% | -5.8% | -2.3% | -3.1% | -4.6% | — |
| Nov 8, 2023 | AMC | -0.42 | -0.41 | +2.4% | 3.34 | +3.0% | -1.0% | +0.9% | +4.2% | +13.8% | +26.9% | — |
| Aug 3, 2023 | AMC | -0.42 | -0.45 | -7.1% | 5.43 | -2.0% | -0.9% | -5.7% | +1.7% | +3.3% | +0.9% | — |
| May 8, 2023 | AMC | -0.38 | -0.43 | -13.2% | 5.54 | -0.7% | +10.3% | +18.8% | +17.0% | +15.0% | +35.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $3.21 | $3.99 | +24.3% | +8.4% | +7.2% | +8.1% | +9.7% | +19.0% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.93 | $3.84 | -2.3% | -2.8% | -13.2% | -19.8% | -15.3% | -16.3% |
| Jan 6 | BofA Securities | Maintains | Buy → Buy | — | $4.06 | $4.06 | +0.0% | +7.4% | +16.5% | +11.3% | +12.3% | +12.8% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $4.05 | $3.91 | -3.5% | +1.0% | +1.7% | +4.7% | +0.2% | -9.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.05 | $3.91 | -3.5% | +1.0% | +1.7% | +4.7% | +0.2% | -9.6% |
| Oct 30 | Citizens | Maintains | Market Outperform → Market Outperform | — | $5.37 | $5.46 | +1.7% | -8.8% | -7.8% | -14.9% | -22.7% | -24.0% |
| Jun 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.60 | $2.64 | +1.5% | +14.2% | +11.5% | +10.4% | +8.1% | +5.0% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.74 | +1.8% | +3.5% | +3.5% | +2.9% | +0.0% | +11.1% |
| Mar 18 | Citizens Capital Markets | Upgrade | Market Perform → Market Outperform | — | $2.77 | $2.84 | +2.5% | -17.7% | -15.5% | -18.4% | -16.6% | -12.6% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.84 | +2.5% | -17.7% | -15.5% | -18.4% | -16.6% | -12.6% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $6.07 | +267.9% | +160.6% | +121.8% | +109.7% | +120.0% | +133.9% |
| Jan 8 | TD Cowen | Upgrade | Hold → Buy | — | $1.65 | $6.07 | +267.9% | +160.6% | +121.8% | +109.7% | +120.0% | +133.9% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.45 | $2.45 | +0.0% | +4.1% | +13.5% | +16.3% | +4.9% | +6.5% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.09 | +2.7% | -4.0% | -5.6% | -11.6% | -14.0% | -19.6% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.76 | $3.50 | -6.9% | -9.8% | -9.3% | -17.6% | -19.9% | -23.1% |
| Nov 5 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $3.76 | $3.50 | -6.9% | -9.8% | -9.3% | -17.6% | -19.9% | -23.1% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $4.66 | $5.00 | +7.3% | +5.4% | +4.9% | +5.2% | +1.9% | +7.1% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.66 | $5.00 | +7.3% | +5.4% | +4.9% | +5.2% | +1.9% | +7.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.49 | $9.26 | -2.4% | -21.0% | -20.3% | -16.6% | -9.4% | -2.3% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.04 | $11.50 | +14.5% | +12.3% | -5.8% | -2.3% | -3.1% | -4.6% |
| Mar 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $10.04 | $11.50 | +14.5% | +12.3% | -5.8% | -2.3% | -3.1% | -4.6% |
| Jan 16 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $6.33 | $6.51 | +2.8% | +0.5% | -3.3% | -10.7% | -20.1% | -14.8% |
| Oct 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.46 | $3.42 | -1.2% | -7.5% | -3.2% | -11.6% | -10.1% | -10.4% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.47 | $5.30 | -3.1% | -7.7% | +0.5% | +5.1% | +4.2% | +1.3% |
| Jan 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.60 | $4.53 | -1.5% | +2.4% | +2.0% | +0.2% | +4.6% | +1.1% |
| Nov 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.81 | $5.61 | -3.4% | -13.9% | -11.4% | -21.5% | -20.7% | -20.3% |
| May 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.90 | $5.04 | +2.9% | +3.1% | -10.4% | -7.6% | -8.6% | -10.2% |
| Aug 6 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.40 | $19.33 | -0.4% | +0.4% | -0.6% | +4.8% | +7.5% | +6.2% |
| Mar 1 | JP Morgan | Maintains | Neutral → Neutral | — | $30.74 | $31.28 | +1.8% | +8.2% | -2.9% | -20.4% | -25.0% | -22.3% |
| Mar 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.74 | $31.28 | +1.8% | +8.2% | -2.9% | -20.4% | -25.0% | -22.3% |
| Mar 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.74 | $31.28 | +1.8% | +8.2% | -2.9% | -20.4% | -25.0% | -22.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Sana Biotechnology, Inc. -- 8-K 5.02: Executive Change
Sana Biotechnology restructured its board class composition by re-appointing Steven D. as a Class III director, rebalancing director membership across the three board classes effective April 22, 2026.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Sana Biotechnology committed capital to Mayo Clinic-partnered programs (SC451, stem-cell islets) with royalty obligations, reducing near-term cash flexibility but validating technology through a prestigious medical institution's backing.
Apr 13
8-K · 8.01
!! High
Sana Biotechnology, Inc. -- 8-K 8.01: Material Event / Announcement
Sana Biotechnology amended its at-the-market offering agreement with TD Cowen, allowing the company to sell common stock opportunistically to raise capital for operations and development.
Mar 3
8-K · 5.02
!!! Very High
Sana Biotechnology, Inc. -- 8-K 5.02: Executive Change
Sana Biotechnology appointed experienced CFO Piper, previously at Scorpion Therapeutics, as Executive Vice President and Chief Financial Officer, strengthening financial leadership during the company's development stage.
Feb 17
Data updated apr 27, 2026 12:06am
· Source: massive.com